Werewolf Therapeutics (NASDAQ:HOWL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Separately, JMP Securities initiated coverage on shares of Werewolf Therapeutics in a research note on Wednesday, April 3rd. They issued a mkt outperform rating and a $12.00 target price on the stock.

Werewolf Therapeutics Trading Down 1.5 %

NASDAQ:HOWL opened at $5.98 on Monday. The stock’s fifty day moving average price is $6.21 and its two-hundred day moving average price is $4.67. Werewolf Therapeutics has a 52-week low of $1.57 and a 52-week high of $8.19. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.10. The business had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.75 million. Werewolf Therapeutics had a negative return on equity of 36.43% and a negative net margin of 256.33%. On average, research analysts forecast that Werewolf Therapeutics will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Financial Perspectives Inc lifted its stake in Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after buying an additional 3,000 shares during the period. Certuity LLC bought a new stake in shares of Werewolf Therapeutics in the 4th quarter valued at about $39,000. Lighthouse Investment Partners LLC bought a new position in Werewolf Therapeutics during the 4th quarter worth approximately $87,000. Denali Advisors LLC acquired a new position in Werewolf Therapeutics during the first quarter valued at approximately $172,000. Finally, PFM Health Sciences LP increased its stake in Werewolf Therapeutics by 35.6% in the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after purchasing an additional 909,895 shares in the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.